

CURRENT REPORT 38/2021

December 17, 2021

Change order to the statement of work

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Issuer", "Company") hereby informs, that today the Company concluded a change order to the statement of work under the framework agreement ("Annex") entered into with Icon Clinical Research Limited, with its registered office in Dublin, Ireland ("Icon"), about which the Issuer informed in the current stock exchange report No. 30/2018 dated October 8, 2018.

The scope of the statement of work includes performing by Icon, on behalf of Company, IND (Investigational New Drug) notification to the US Food and Drug Administration and conducting Phase I clinical trials for the Issuer's lead project RVU120 (SEL120). The change order to the statement of work is a result of updating the protocol for the study conducted in patients with relapse and refractory AML and HRMDS, and increased oversight over U.S. sites including increased frequency of monitoring visits to the sites, as well as an extension of the study by 13 months compared to the timelines expected in 2018. The Company expects to determine the recommended dose for the Phase II of the study in 2022.

The original value of the agreement amounted to EUR 3.841.209,06 (PLN 16.560.220,50 converted at the exchange rate of 1 EUR = PLN 4.3112 as of October 8, 2018). Taking into account previous changes to the statement of work and the last change order introduced by the Annex, the total value of the agreement will to EUR 5.623.128,00 (PLN 26.054.201,27 converted at the exchange rate of the National Bank of Poland as of December 17, 2021 1 EUR = 4.6334 PLN).

Terms of the Annex do not differ from those commonly used for this type of documents.

Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR)

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board